1297P RATIONALE 307: Tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) in patients (pts) who were smokers vs non-smokers